Trial Profile

Phase 1b study of ERAS-3490 in patients with KRAS G12Cm NSCLC

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 27 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ERAS-3490 (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms AURORAS-1

Most Recent Events

23 Mar 2023 According to an Erasca media release, initial data expected in 2024.
13 Dec 2022 According to an Erasca media release, company announced the United States Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ERAS-3490.
18 Nov 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com